Sex and MS: relationship with depression, fatigue and disability
1 September 2017
This research looks at the relationship between sexual problems in MS and symptoms, such as depression, fatigue and level of disability.
How does staying in hospital affect your MS?
9 August 2017
Research study looked at the impact hospital admissions can have on multiple sclerosis disability levels.
Does benign MS stay benign MS?
13 July 2017
Researchers gathered data on people considered to have benign multiple sclerosis to see how many would still be classified as benign MS ten years later.
Understanding how and why MS fatigue fluctuates throughout the day
19 May 2017
In this study fatigue was monitored throughout the day to understand how mood, stress and physical activity contribute to fluctuations.
Simvastatin trial planned for secondary progressive multiple sclerosis
9 May 2017
The launch of a trial involving more than 1000 people with secondary progressive MS (SPMS) has been announced. The trial will investigate whether simvastatin can slow down disability progression.
When can you safely stop taking disease modifying drugs?
22 March 2017
This study aimed to get a clearer picture of who can stop taking DMDs without risk of a return of MS activity.
Research seeks to understand myelin repair
14 March 2017
Researchers have discovered a protein that encourages the regrowth of myelin and may lead to new types of treatment for MS in the future
Promising results from long term studies of stem cell transplants
24 February 2017
Highlights two recently published studies which have reported promising results on levels of disability in people with MS five years after stem cell transplants.
Can ocrelizumab slow down disability in primary progressive MS
10 February 2017
Ocrelizumab is an experimental new treatment being tested for both relapsing and primary progressive MS; clinical trial results for PPMS are summarised.
Do people want to know about the future course of their MS?
27 January 2017
Research into how people currently manage the uncertainty of MS and how they might feel about being given their own personal prognosis.
Positive trial results published for primary progressive MS drug
22 December 2016
The full results of the latest ocrelizumab trials have been published in the New England Journal of Medicine.
High-dose biotin (MD1003) investigated as a potential treatment for progressive MS
6 December 2016
High-dose biotin (also known as MD1003 and Cerenday), is an experimental new treatment for progressive MS; clinical trial results reported.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.